Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 25.15 USD -1.8% Market Closed
Market Cap: 1.5B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+4%
Revenue
Forecast
+6%
Operating Income
Forecast
+10%
Net Income
Forecast
+2%

Wall Street
Price Targets

JANX Price Targets Summary
Janux Therapeutics Inc

Wall Street analysts forecast JANX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JANX is 85.22 USD with a low forecast of 25.25 USD and a high forecast of 210 USD.

JANX Lowest Forecast
Wall Street Target
25.25 USD
0% Upside
JANX Average Forecast
Wall Street Target
85.22 USD
239% Upside
JANX Highest Forecast
Wall Street Target
210 USD
735% Upside
Lowest
Price Target
25.25 USD
0% Upside
Average
Price Target
85.22 USD
239% Upside
Highest
Price Target
210 USD
735% Upside
Janux Therapeutics Inc Competitors:
Price Targets
1167
Jacobio Pharmaceuticals Group Co Ltd
56% Downside
INCY
Incyte Corp
13% Upside
K
4584
Kidswell Bio Corporation
83% Upside
LYEL
Lyell Immunopharma Inc
67% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
56% Downside
INCY
Incyte Corp
13% Upside
K
4584
Kidswell Bio Corporation
83% Upside
LYEL
Lyell Immunopharma Inc
67% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
12% Downside
CSL
CSL Ltd
33% Upside
PBYI
Puma Biotechnology Inc
30% Upside
BMRN
Biomarin Pharmaceutical Inc
68% Upside

Revenue
Forecast

Revenue Estimate
Janux Therapeutics Inc

The compound annual growth rate of Janux Therapeutics Inc's revenue for the next 3 years is -11%.

N/A
Past Growth
-11%
Estimated Growth
Estimates Accuracy
27%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Janux Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Janux Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-37%
Average Miss
What are analyst estimates?

See Also

Summary
JANX intrinsic value, competitors valuation, and company profile.
DCF Valuation
JANX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JANX stock valuation using valuation multiples.
Wall Street Estimates
JANX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JANX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is JANX's stock price target?
Price Target
85.22 USD

According to Wall Street analysts, the average 1-year price target for JANX is 85.22 USD with a low forecast of 25.25 USD and a high forecast of 210 USD.

What is Janux Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

The compound annual growth rate of Janux Therapeutics Inc's revenue for the next 3 years is -11%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 267,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.